Thromboembolism Risk and Treatment of Therapeutic Agents for Inflammatory Bowel Disease
10.3969/j.issn.1008-7125.2023.07.006
- VernacularTitle:炎症性肠病治疗药物的血栓栓塞风险与治疗现状
- Author:
Xinglian YU
1
;
Chuanfei LI
;
Lin LÜ
Author Information
1. 重庆医科大学附属第二医院消化内科(400010)
- Keywords:
Inflammatory Bowel Disease;
Thromboembolism;
Pharmacotherapy;
Anticoagulant Therapy
- From:Chinese Journal of Gastroenterology
2023;28(7):441-448
- CountryChina
- Language:Chinese
-
Abstract:
Patients with inflammatory bowel disease(IBD)have an increased risk of thromboembolism.Recent reports on Janus kinases inhibitors and thromboembolic adverse events have revealed that IBD therapeutic drug play an essential role in modifying this risk in a pro or antithrombotic manner,in addition to the increased risk of thrombosis of IBD itself.In this review,we provide an overview of the current understanding on thrombosis risk,mechanism and anticoagulant therapy of IBD drugs.While controlling the activity of the disease with appropriate therapy,thromboembolism prophylaxis and personalized treatment o should be emphasized.
